Month: June 2025

AI-Media Redefines Global Accessibility with LEXI Voice at InfoComm 2025

Written by Customer Service on June 6, 2025. Posted in Public Companies.

Booth #5389 + AVIXA TV Studio: Experience Real-Time Multilingual Translation at ScaleInfoComm 2025 x AI-MediaVisit AI-Media at InfoComm 2025, Booth #5389NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) — AI-Media (ASX: AIM), the global leader in AI-powered language solutions, will debut its game-changing LEXI VOICE platform at InfoComm 2025, setting a new benchmark for live, multilingual accessibility. Attendees can visit Booth #5389 or tune in via AVIXA TV Studio to witness how LEXI VOICE instantly translates spoken content into natural-sounding audio across 100+ languages – redefining how the world connects. Following its acclaimed launch at NAB Show 2025, LEXI VOICE combines ultra-accurate live captioning, AI-driven translation, and lifelike voice synthesis to deliver seamless, simultaneous multilingual output in real...

Form 8.3 – AXA INVESTMENT MANAGERS: Unite Group plc.

Written by Customer Service on June 6, 2025. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: AXA Investment Managers S.A.(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Unite Group plc, The(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For...

Auction result of Treasury Bonds – RIKB 27 0415 – RIKB 35 0917

Written by Customer Service on June 6, 2025. Posted in Public Companies.

Series RIKB 27 0415 RIKB 35 0917Settlement Date 06/12/2025 06/12/2025Total Amount Allocated (MM) 1,550 5,130All Bids Awarded At (Price / Yield) 100.735 / 7.530 100.325 / 6.950Total Number of Bids Received 11 22Total Amount of All Bids Received (MM) 1,815 6,300Total Number of Successful Bids 8 17Number of Bids Allocated in Full 8 17Lowest Price / Highest Yield Allocated 100.735 / 7.530 100.325 / 6.950Highest Price / Lowest Yield Allocated 100.825 / 7.480 100.560 / 6.920Lowest Price / Highest Yield Allocated in Full 100.735 / 7.530 100.325 / 6.950Weighted Average of Successful Bids (Price/Yield) 100.771 / 7.510 100.448 / 6.930Best Bid (Price / Yield) 100.825 / 7.480 100.560 / 6.920Worst Bid (Price / Yield) 100.700 / 7.560 100.100 / 6.980Weighted Average of All Bids Received (Price...

Immix Biopharma Attends FDA CEO Forum in Washington DC

Written by Customer Service on June 6, 2025. Posted in Public Companies.

– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. – LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it was selected by FDA, and attended, the FDA CEO forum led by FDA Commissioner Marty A. Makary, M.D., M.P.H. and team at FDA headquarters in Silver Spring, MD, on June 5, 2025. Per FDA, the purpose of the meeting is to gather direct input from biotechnology and pharmaceutical leaders on how the FDA can modernize its regulatory framework to better support innovation and patient access to safe and effective therapies. FDA Commissioner Marty A. Makary, M.D., M.P.H. stated, “These...

Bango 2024 Full Year Results and Outlook

Written by Customer Service on June 6, 2025. Posted in Earnings Releases And Operating Results.

CAMBRIDGE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) — Bango (AIM: BGO), today announces its full year results for the 12 months ended 31 December 2024 and provides an update on current trading and outlook for 2025. FY24 Financial Overview:Results for the 12 months ended 31 December 2024 FY24 FY23 YoY Change Transactional Revenue1 $36.2M $32.7M +11%DVM & One Off Revenue2 $17.2M $13.4M +28% Total Revenue $53.4M $46.1M +16% Annual Recurring Revenue (ARR) 3 $14.0M $8.8M +59%Net Retention4 125% 137% Adjusted EBITDA5 $15.3M $6.4M +139% Loss After Tax ($3.7M) ($8.8M) $5.1M Net (debt)/cash at 31 December6 ($1.8M) ($4.0M) $2.2MFY24 Operational highlights:9 new Digital Vending Machine® (DVMTM) license customers (total 27 at end of 2024) 110...

Verizon declares quarterly dividend on June 6

Written by Customer Service on June 6, 2025. Posted in Dividend Reports And Estimates.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) — The Board of Directors at Verizon Communications Inc. (NYSE, Nasdaq: VZ) today declared a quarterly dividend of 67.75 cents per outstanding share, unchanged from the previous quarter. The quarterly dividend is payable on August 1, 2025 to Verizon shareholders of record at the close of business on July 10, 2025. Verizon continues to take a strategic and disciplined approach to achieving its financial goals by focusing on targeted customer segments and integrating its services to deliver greater personalization. Building on its financial strength, Verizon continues to invest in its business and drive innovation to better serve its customers. “As the nation’s leader in mobility and broadband for consumers and businesses, we create great experiences for a broad and high-quality base of customers,”...

Judgment of the Administrative Regional Court of the Republic of Latvia regarding KIA Auto AS and TKM Grupp AS

Written by Customer Service on June 6, 2025. Posted in Public Companies.

On 5th of June 2025, the Administrative Regional Court of the Republic of Latvia delivered a judgment in a case that has been ongoing for over ten years, concerning the legality of the decision made by the Latvian Competition Council on August 7, 2014, regarding TKM Grupp AS and its subsidiary KIA Auto AS (initial company announcement dated August 21, 2014). KIA Auto AS and TKM Grupp AS express their regret that, despite the extensive explanations, statements, and additional evidence they submitted, these were not taken into account, and the decision of the Latvian Competition Authority was upheld. KIA Auto AS and TKM Grupp do not agree with the findings set forth in the judgment and will submit a cassation claim to the Supreme Court of the Republic of Latvia. The Competition Council alleged in its 2014 decision that in order not to lose...

Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair

Written by Customer Service on June 6, 2025. Posted in Public Companies.

Mr. Chin brings over 20 years of financial experience across public and private healthcare organizations Mr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financing Mr. Chin’s appointment strengthens Biomerica’s corporate governance and financial oversight as Biomerica scales commercialization effortsIRVINE, Calif., June 06, 2025 (GLOBE NEWSWIRE) — Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products, today announced that Eric B. Chin has been appointed to the Company’s Board of Directors, effective June 4, 2025. Mr. Chin will serve as Chairperson of the Audit Committee and as a member of the Nominating and Corporate Governance Committee and the Compensation Committee. Mr....

LHV Group’s own share acquisition transactions

Written by Customer Service on June 6, 2025. Posted in Public Companies.

AS LHV Group announces that on 5 June 2025, it has acquired the company’s own shares on the Nasdaq Tallinn Stock Exchange as follows:Date Aggregated volume Weighted average price per day (EUR)05.06.2025 7,200 3.75 LHV Group is acquiring its own shares based on the resolution of the company’s general meeting of shareholders held on 26 March 2025, and under the conditions decided by the Supervisory Board. The authorized agent for the transactions is AS LHV Pank. Summary data of the acquisitions will be disclosed no later than on the seventh trading day after the transaction and will be made available to the Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on LHV Group’s investor website. LHV Group is the largest domestic financial group and capital provider in Estonia. LHV Group’s key subsidiaries...

USDA Designates Cibus’ Herbicide Tolerance Canola Trait HT2 as Not Regulated Under USDA’s Biotechnology Regulations

Written by Customer Service on June 6, 2025. Posted in Public Companies.

This action follows the USDA’s recent designation of Cibus’ disease resistance traits in Canola as not regulated, continuing Cibus’ product development momentum in the globally important Canola crop SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) — Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced today that its most recent trait for its herbicide tolerance trait (HT2) in Canola has been designated as “not regulated” by the United States Department of Agriculture’s Animal and Plant Health Inspection Service (USDA-APHIS) Biotechnology Regulatory Services (BRS) as Plant Pests or Which There is Reason to Believe Are Plant Pests, as described in 7 CFR part 340. Dr. Peter Beetham, Co-Founder and Interim Chief Executive Officer of Cibus,...

Month: June 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals